Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth

Company Boasts 51 Late-Stage Candidates

 
• By Andrew McConaghie
  
Roche_Basel
Roche is banking on its sector-leading R&D expenditure to pay off over the next 5-10 years. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip